Accessibility Menu
Panbela Therapeutics logo

Panbela Therapeutics(OTC) PBLA

Market Cap$53.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 YearN/A
1 Year-93%
1 Month+122%
$0.01
+0%
+0.00Today
Panbela Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-22
Panbela Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-07-10
1 month+122%USD 0.012026-06-22
3 month+0%USD 0.012026-04-23
Year to date+5,450%USD 0.002025-12-31
1 year-92.97%USD 0.162025-07-22
Since inception-100%USD 719,994.242015-10-19

Panbela Therapeutics Financials at a Glance

Market Cap

$53.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$27.91M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3266.83 (High)

Price

$0.01

Volume

10

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $2.50

Estimated Earnings Date

Aug 12, 2026

PBLA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Panbela Therapeutics

Panbela Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients. The company primarily targets pancreatic disorders, including pancreatic cancer and pancreatitis, while also exploring treatments for other oncology indications.

Products and Services
  • Flagship drug SBP-101 in Phase Ia/Ib clinical trials
  • Research on therapies for colorectal and ovarian cancers
  • Focus on neoadjuvant treatments for pancreatic cancer
Growth Outlook
  • Continued clinical trials for SBP-101 may lead to significant advancements
  • Potential expansion into additional oncology markets enhances growth prospects
  • Strategic partnerships could accelerate development timelines
Financial Highlights
  • Recent quarterly net income of -$7.18 million reflects ongoing R&D investments
  • Cash and cash equivalents decreased to $142,000 in Q3 2024
  • Operating expenses totaled $7.16 million in the latest quarter
Panbela Therapeutics, Inc. is positioned in the biotechnology sector, with a focus on addressing critical unmet needs in cancer treatment. The company's flagship drug, SBP-101, is currently undergoing clinical trials, which could pave the way for future revenue streams. Despite recent financial challenges, including significant operating losses, the ongoing research and development efforts indicate a commitment to innovation in cancer therapies. The potential for strategic partnerships and expansion into new markets may further enhance the company's growth trajectory. Investors may find interest in the company's unique focus on pancreatic disorders and its broader oncology research initiatives.
AI Generated • Jul 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Jennifer K. Simpson, PhD

Website

www.panbela.com

Headquarters

Waconia, MN 55387, US

PBLA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

396.00%

Return on Capital

-10597.93%

Return on Assets

-214.06%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$53.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.85M

Volume

10

Avg. Volume

480.194

Financials (TTM)

Gross Profit

-$29.04M

Operating Income

-$36.20M

EBITDA

-$26.40M

Operating Cash Flow

-$15.57M

Capital Expenditure

$0.00

Free Cash Flow

-$15.57M

Cash & ST Invst.

$142.00K

Total Debt

$6.39M

Panbela Therapeutics Performance Analysis

Panbela Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
Panbela Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31N/A
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Panbela Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -20,773.68N/A
20222022-12-31USD -40,748.6496.2%
20232023-12-31USD -232.43-99.4%
Panbela Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3199.9%
Q12024-03-31-8251.6%
Q22024-06-3035.5%
Q32024-09-30-0.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.17M

+8.7%

Gross Margin

0.00%

N/A

Market Cap

$53.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.70K

N/A

Employees

7

N/A

Net Income

-$7.17M

+8.4%

EBITDA

-$6.73M

+13.5%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$142.00K

-84.3%

Total Debt

$6.39M

+23.1%

Accounts Receivable

$332.00K

+114.2%

Inventory

$0.00

N/A

Long Term Debt

$3.19M

-23.8%

Short Term Debt

$3.20M

+220.0%

Return on Assets

-2.14%

N/A

Return on Invested Capital

99.41%

N/A

Free Cash Flow

-$2.12M

+68.2%

Operating Cash Flow

-$2.12M

+68.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVOSNovo Integrated Sciences, Inc.
$0.00+5.71%
OMHEOMNI Health, Inc.
$0.00+0.00%
BRAXFBraxia Scientific Corp.
$0.00+0.00%
MOBOMobile Lads Corp.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About PBLA

What is the current price of Panbela Therapeutics?

Panbela Therapeutics is trading at $0.01 per share.

What is the 52-week range for Panbela Therapeutics?

Over the past 52 weeks, Panbela Therapeutics has traded between $0.01 and $2.50.

How much debt does Panbela Therapeutics have?

As of the most recent reporting period, Panbela Therapeutics reported total debt of $6.39M.

How much cash does Panbela Therapeutics have on hand?

Panbela Therapeutics reported $142.00K in cash and cash equivalents in its most recent financial results.

What is Panbela Therapeutics’s dividend yield?

Panbela Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services